<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584818</url>
  </required_header>
  <id_info>
    <org_study_id>127-013</org_study_id>
    <nct_id>NCT00584818</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease</brief_title>
  <official_title>A Phase 2 Dose-Finding Clinical Trial of CARDIOsphere® (PB127) in Normal Volunteers and in Patients With Known or Suspected Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Point Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Point Biomedical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of&#xD;
      coronary artery disease when used with cardiac ultrasound. This study also evaluates the&#xD;
      safety of PB127.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the minimum effective dose of PB127</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the optimal stress infusion rate of PB127</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of PB127 MPE using the dose and stress infusion rate identified in Stages 1 and 2</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of PB127</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">205</enrollment>
  <condition>Healthy</condition>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB127 for Injectable Suspension</intervention_name>
    <description>Stages 1 &amp; 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.&#xD;
Stage 3 - will utilize infusion rate and dose established in Stages 1 &amp; 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions.</description>
    <other_name>CARDIOsphere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Stages 1 and 2&#xD;
&#xD;
          1. Men and women&#xD;
&#xD;
          2. Ages 18 30&#xD;
&#xD;
          3. Normal volunteers&#xD;
&#xD;
          4. No history (or suspicion) of CAD&#xD;
&#xD;
        Stage 3&#xD;
&#xD;
          1. Men and women with known or suspected CAD&#xD;
&#xD;
          2. Ages 18 years and older&#xD;
&#xD;
          3. Scheduled for or undergone clinically indicated coronary angiography within 28 days&#xD;
             prior to or following Study Day 1&#xD;
&#xD;
               1. Coronary angiography within 28 days prior to Study Day 1 and/or SPECT must have&#xD;
                  been non-interventional&#xD;
&#xD;
               2. Coronary angiography images available in digital format (non cine) for&#xD;
                  transmission to core laboratory&#xD;
&#xD;
          4. Scheduled for or undergone SPECT within 28 days prior to or following Study Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to provide written informed consent&#xD;
&#xD;
          2. Women who are pregnant or lactating&#xD;
&#xD;
          3. Known hypersensitivity or known contraindication to:&#xD;
&#xD;
               1. Dipyridamole&#xD;
&#xD;
               2. Ultrasound contrast agents (including PB127 and excipients)&#xD;
&#xD;
               3. Blood, blood products, albumin, egg whites, or protein&#xD;
&#xD;
          4. Use of caffeine or xanthine containing products within the 24 hours prior to PB127&#xD;
             administration on Study Day 1 (Stages 2 and 3)&#xD;
&#xD;
          5. Previous exposure to PB127&#xD;
&#xD;
          6. Inadequate echocardiographic windows&#xD;
&#xD;
          7. Heart transplant&#xD;
&#xD;
          8. Known right to left shunt, including atrial septal defect&#xD;
&#xD;
          9. History of CABG&#xD;
&#xD;
         10. Current uncontrolled ventricular tachycardia, atrial fibrillation, atrial tachycardia,&#xD;
             or atrial flutter&#xD;
&#xD;
         11. Pacemaker or defibrillator&#xD;
&#xD;
         12. Unstable angina grade CCS Class IV severity with ongoing symptoms and/or ongoing&#xD;
             infusion of IV nitroglycerin&#xD;
&#xD;
         13. Second degree or greater heart block&#xD;
&#xD;
         14. Hypertension (SPB &gt;200 and/or DBP &gt;110 mmHg on two consecutive readings within 1 hour&#xD;
             prior to PB127 administration)&#xD;
&#xD;
         15. Hypotension (SPB &lt;90 mmHg on two consecutive readings within 1 hour prior to PB127&#xD;
             administration)&#xD;
&#xD;
         16. Severe aortic stenosis (&gt;100 mmHg peak transvalvar gradient or &lt;0.6 cm2 estimated&#xD;
             valve area)&#xD;
&#xD;
         17. Pulmonary edema within the 7 days prior to Study Day 1&#xD;
&#xD;
         18. Resting oxygen saturation of less than 90%&#xD;
&#xD;
         19. Q wave MI or major surgery within the 7 days prior to Study Day 1&#xD;
&#xD;
         20. PTCA within the 28 days prior to Study Day 1&#xD;
&#xD;
         21. Chronic obstructive pulmonary disease or bronchospastic airway disease which, in the&#xD;
             opinion of the Investigator, is significant enough to contraindicate dipyridamole&#xD;
&#xD;
         22. Known history of severe pulmonary hypertension characterized by estimated pulmonary&#xD;
             artery systolic pressure of &gt;50 mmHg&#xD;
&#xD;
         23. Liver disease, characterized by or including one or more of the following&#xD;
&#xD;
               1. Elevated total bilirubin &gt; upper limit of normal&#xD;
&#xD;
               2. Currently elevated hepatic enzymes &gt;3X upper limit of normal&#xD;
&#xD;
         24. Medical conditions or other circumstances that would significantly decrease the&#xD;
             chances of obtaining reliable data or achieving the study objectives (i.e., drug&#xD;
             dependence, psychiatric disorder, dementia, or associated illness); extenuating&#xD;
             circumstances or medical conditions that make it unlikely that a patient can complete&#xD;
             the clinical trial or follow up evaluations; or other reasons for expected poor&#xD;
             compliance with the clinical investigator's instructions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Ehlgen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>POINT Biomedical Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach VA Medical Center Cardiology Division</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Division of Cardiology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfieri Cardiology</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiology Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cardiovascular Studies Kramer and Crouse Cardiology</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Androscoggin Cardiovascular Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cardiovascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Healthcare Network Brackenridge Hospital</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Cardiology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cardiovascular Research Institute Spokane Cardiology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tom Ottoboni PhD/Chief Operating Officer</name_title>
    <organization>POINT Biomedical Corp.</organization>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>chest pain</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>SPECT</keyword>
  <keyword>angiogram</keyword>
  <keyword>ultrasound</keyword>
  <keyword>echocardiogram</keyword>
  <keyword>perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

